BC Innovations | Jun 27, 2017
Distillery Techniques


TECHNOLOGY: Plasma markers Blood levels of panel of miRNAs could help predict patient responses to antidepressants. In postmortem prefrontal cortex samples from patients, levels of miR-24-3p , miR-146a-5p and miR-146b-5p and miR-425-3p were lower than in...
BC Innovations | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

The publication this month of the crystal structure of the serotonin transporter unquestionably marked a technical watershed, and solved long-asked questions about why similar compounds bind the protein differently. Historically, the target revolutionized depression, spawning...
BC Week In Review | Dec 7, 2015
Clinical News

Lexapro escitalopram oxalate regulatory update

Mochida and Mitsubishi Tanabe Pharma Corp. (Tokyo:4508, Osaka, Japan) said Japan approved an expanded label for Lexapro escitalopram oxalate to treat social anxiety disorder. The once-daily allosteric selective serotonin reuptake inhibitor (SSRI) is marketed in...
BC Extra | Aug 20, 2015
Company News

Lundbeck restructuring

H. Lundbeck A/S (CSE:LUN) climbed DKK32.10 (19%) to DKK201 on Wednesday after unveiling restructuring plans designed to cut costs and regain profitability. The restructuring is Lundbeck's first major move since Kare Schultz took the helm...
BioCentury | Nov 10, 2014

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
BioCentury | Aug 11, 2014

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
BioCentury | May 12, 2014

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
BioCentury | Feb 24, 2014

Tree hugging

Forest Laboratories Inc. 's efforts to renew its growth by in-licensing commercial stage products and cutting costs culminated in last week's $25 billion takeout offer from Actavis plc . Recent Forest investors are getting about a...
BioCentury | Feb 10, 2014

Confident roll of the dice(r)

Underwriters for Dicerna Pharmaceuticals Inc. 's IPO took the rare step of waiving a lockup period for the RNAi play - a move that could give some existing shareholders a free hand to immediately realize some...
BioCentury | Nov 11, 2013

OrbiMed's high five

At a time when many life science VCs are raising smaller funds, OrbiMed Advisors closed what might be the largest pure venture fund in over a decade, raising more than $735 million from LPs who...
Items per page:
1 - 10 of 196